

SEP. 26, 2002 3:17PM

PLA LEGAL DEPT.

NO. 897 F. E. 5



Attorney Docket No.: 3985.240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al.

Application No.: 09/398,365

Group Art Unit: 1637

RECEIVED

Filed: September 17, 1999

Examiner: Siew, J.

OCT 08 2002

Confirmation No: 9987

TECH CENTER 1600/2900

For: Acylated Insulin

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

Commissioner for Patents
Washington, DC 20231
Attn.: Monica Graves

Sir:

Upon review of the file for the above-identified application, the undersigned noted that in the Request for Continued Examination ("RCE") filed September 19, 2002, the box authorizing the Patent Office to charge the fee required under 37 C.F.R. 1.17(e) for the filing of an RCE was inadvertently not checked.

This letter is to therefore authorize the Commissioner of Patents to charge the RCE fee required under 37 C.F.R. 1.17(e) to Deposit Account No. 14-1447. A duplicate copy of this sheet is enclosed.

As the RCE and an accompanying Amendment and Information Disclosure Statement ("IDS") were filed on September 19, 2002 and in response to an "ex-parte Quayle" Office, Action mailed June 19, 2002, if it is deemed that a one month extension of time is necessary for the entry and consideration of this paper and of the RCE and

accompanying Amendment and IDS filed on September 19, 2002, please charge the fee of \$110.00 for a one (1) month extension to Deposit Account No. 14-1447.

Respectfully submitted,

Date: September 26, 2002

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800



SEP. 26, 2002 3:17PM FAX TO LEGAL DEPT.

NO. 837 F. 1/5

REC'D F
-153

Attorney Docket No.: 3985.240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Havelund et al.

ACT 08 2002

Serial No.: 09/398,365

Group Art Unit: 1637

Filed: September 17, 1999

Examiner: Siew, J.

Confirmation No: 9987

TECH CENTER 1600 2900

For: Acylated Insulin

CERTIFICATE OF FACSIMILE TRANSMISSION

Director - U.S. Patent and Trademark Office
Washington, DC 20231
Attn.: Monica Graves

Sir:


I hereby certify that the attached correspondence comprising:

1. Authorization To Charge Deposit Account (in duplicate)

was sent to the United States Patent and Trademark Office by telefax to the attention of the Certification Branch, fax number (703) 746-3014.

Respectfully submitted,

Date: September 26, 2002


Maya Faison-Phillip
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
609-987-5800